US 8778999

I'll search for authoritative information on this specific patent number, including any 2026 CAFC docket activity.

Let me search more specifically for litigation and any appellate activity involving this patent.

Let me check for any Federal Circuit appeal of the 2021 judgment and details on the reissue patent.

US 8,778,999 B2 — Analyst Summary

Important scope note on my search: I was able to retrieve and corroborate the bibliographic data, abstract, and the district‑court litigation record for this patent. I was not able to retrieve an authoritative full claims listing (all independent and dependent claims verbatim), and I found no evidence of any 2026 CAFC docket activity involving this patent. Where I am inferring rather than citing, I say so explicitly.

1. Bibliographic data (corroborated across Google Patents, EPO Global Patent Index, FDA Orange Book letter, and D.N.J. opinion)

2. Abstract (verbatim)

"The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye."

3. Independent claim — plain language

I can state independent claim 1 with high confidence because it is quoted verbatim in the D.N.J. trial opinion (Sun Pharma Global FZE v. Lupin Ltd., No. 18‑2213 (FLW)):

"[a] topical ophthalmic composition formulated for application to the eye, said composition comprising a therapeutically effective amount of bromfenac and a flowable crosslinked carboxy-containing polycarbophil and mucoadhesive polymer, wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5."

In plain terms, claim 1 requires four things:

1. A topical ophthalmic composition (an eye drop‑type product).
2. A therapeutically effective amount of bromfenac as the active NSAID (the claim does not itself fix a numeric concentration; note the 0.075% commercial strength).
3. A specific vehicle: a flowable, crosslinked, carboxy‑containing polycarbophil mucoadhesive polymer — i.e., the DuraSite®‑type lightly crosslinked acrylic acid polymer described in U.S. Pat. No. 5,192,535 (Davis et al.).
4. Two numeric parameters: viscosity about 1,000–3,400 cps and pH about 7.4–8.5.

Note the internal inconsistency in the specification, which became the litigation battleground: the detailed description states viscosities of "about 1,000 to about 2,000 … cps" (and "about 1,500 cps") and only alternatively mentions "1000 to 3400 cps as measured with a Brookfield cone and plate viscosity DV‑II+ with the spindle No. CP‑52 at 6 rpm." The claim adopts the 1,000–3,400 cps figure.

Other independent claims — uncertain. The specification sets out parallel "aspects" that read as claim‑type categories: (a) a sustained‑release bromfenac delivery system (polymer ~0.5–1.5 wt%, bromfenac ~0.005–0.5 wt%), (b) a process/method for therapeutic treatment of the eye, and (c) combination‑therapy compositions (bromfenac + ketorolac + mucoadhesive polymer). I cannot confirm from an authoritative claims listing which of these are actually recited as independent claims in the issued patent, how many independent claims there are, or the exact wording of the remaining claims. Treat that mapping as an inference from the specification, not a verified claim set.

4. Litigation of record

District court (the "Family has litigation" entry):

• Sun Pharma Global FZE et al. v. Lupin Ltd. et al., D.N.J. Civil Action No. 3:18‑cv‑02213 (FLW‑TJB), Judge Freda L. Wolfson. Filed Feb. 14–15, 2018; venue link: https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A18-cv-02213
• Triggered by Lupin's Paragraph IV certification in ANDA No. 211239 (bromfenac ophthalmic solution 0.075%, generic of BromSite).
• Five‑day remote bench trial, March 2021. Opinion at 2021 WL 4473411 (D.N.J. Sept. 30, 2021); docket entry 244.
• Holdings: (i) Lupin's ANDA product does not literally infringe; (ii) regardless, the '999 patent is invalid as obvious over U.S. Pat. No. 6,159,458 ("Bowman I"); (iii) invalid as indefinite under Nautilus because the viscosity‑measuring protocol does not specify spin time; (iv) no inequitable conduct by Dr. Bowman for not disclosing Bowman I. Case terminated Sept. 30, 2021.
• FDA's 2024 ANDA approval letter for Lupin confirms the litigation was "dismissed" and lists the '999 patent as expiring August 7, 2029.

Successor/reissue patent: As of the 2026 pleading record, Sun has asserted RE50,218 (the '218 patent) against Solaris Pharma Corp., D.N.J. 3:26‑cv‑04286 (filed Apr. 22, 2026, Judge Padin), over Solaris's ANDA No. 220440 (bromfenac 0.075%). Google Patents' page for US 8,778,999 cross‑references US RE50218 E1, deriving from application US 17/726,665 (priority recorded 2022‑04‑22). I therefore infer with moderate-to-high confidence that RE50,218 is the reissue of the '999 patent and that this explains the "Ceased" legal status of US 8,778,999 — but I did not retrieve a face‑of‑document statement of that reissue relationship, so please verify independently.

5. CAFC 2026 dockets — no hits found

I searched the CAFC site's 2026 daily dockets/opinion pages and general web sources for any 2026 appeal, mandamus, or other Federal Circuit docket referencing 8,778,999 or 8778999, including in connection with Sun Pharma, Lupin, InSite Vision, or BromSite. I found nothing. Candidate explanations, none confirmed:

• The 2018 case was resolved at the district court level in 2021 and appears not to have produced a 2026 CAFC appeal under this patent number.
• Any 2026 appellate activity may be docketed under the reissue patent number (RE50,218) rather than under 8,778,999.

Caveat: The Federal Circuit does not expose a single free‑text docket search that I could exhaustively query, and PACER/RECAP coverage lags. A negative result here is not proof that no such filing exists. If a binding negative is required, this should be verified via PACER/RECAP docket search for both "8,778,999" and "RE50,218," and via the CAFC clerk's docket system.

6. Items I did not verify (stated explicitly rather than guessed)

• The complete, verbatim claim set (claims 2–N) and the exact count of independent claims.
• Whether the patent's claims were amended, cancelled, or confirmed in the RE50,218 reissue proceeding.
• Whether the 2021 invalidity judgment was ever appealed, settled, or otherwise superseded.
• Any 2026 CAFC docket number for a case involving this patent number.

Sources consulted

• Google Patents, US8778999B2: https://patents.google.com/patent/US8778999/en
• EPO Global Patent Index, EP 2403493 B1 (family listing): https://data.epo.org/gpi/EP2403493B1.pdf
• D.N.J. opinion, No. 3:18‑cv‑02213, ECF 244 (Sept. 30, 2021): https://www.docketalarm.com/cases/New_Jersey_District_Court/3--18-cv-02213/SUN_PHARMA_GLOBAL_FZE_et_al_v._LUPIN_LIMITED_et_al/docs/244.pdf
• FDA ANDA approval letter, ANDA 211239 (2024): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/211239Orig1s000ltr.pdf
• DrugPatentWatch, patent 8,778,999: https://www.drugpatentwatch.com/p/patent/8778999
• Solaris Pharma complaint, D.N.J. 3:26‑cv‑04286: https://ia801601.us.archive.org/12/items/gov.uscourts.njd.[596429](/patent/596429)/gov.uscourts.njd.596429.1.0.pdf
• CAFC 2026 docket pages (Feb. 2, 2026; Apr. 10, 2026): https://www.cafc.uscourts.gov/2026/02/02/ , https://www.cafc.uscourts.gov/2026/04/10/

I'll research litigation involving US 8778999. Let me run several searches.

Let me dig into the specific New Jersey case referenced in the patent record and related litigation.

Let me check for PTAB proceedings and any other cases involving this patent.

Litigation involving U.S. Patent No. 8,778,999 (the "’999 patent")

I found one district-court case in which U.S. Pat. No. 8,778,999 was actually asserted, plus a related 2026 case asserting the reissue patent (RE50,218) rather than the ’999 patent itself. Details below, with sources.

Case 1 — The Lupin action (the only case asserting the ’999 patent)

Citations:

• Google Patents litigation record for US 8,778,999 (links D.N.J. case 3:18-cv-02213): https://patents.google.com/patent/US8778999/en
• CourtListener docket #244 (Opinion, D.E. 244, Sept. 30, 2021): https://www.courtlistener.com/docket/[6668689/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=6668689-0244)/sun-pharmaceutical-industries-ltd-v-lupin-limited/
• CourtListener docket #260/#261 (Stipulation and Order of Dismissal With Prejudice, Feb. 2022): https://www.courtlistener.com/docket/[6668689/260](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=6668689-0260)/sun-pharmaceutical-industries-ltd-v-lupin-limited/
• Justia PDF of the Opinion: https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2018cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/0.pdf
• DrugsPatentWatch BROMSITE litigation table (’999, D.N.J. 3:18-cv-02213, filed 2018-02-15, terminated 2021-09-30): https://www.drugpatentwatch.com/p/alphasignals/litigation/drugname/index.php?query=BROMSITE
• FDA approval letter, ANDA 211239 (recites the 45-day suit and dismissal): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/211239Orig1s000ltr.pdf
• ParagraphFour entry for BromSite® / Lupin: https://paragraphfour.com/members/gregoryglass/activity/11848/
• Robinson & Kaplan case note: https://www.robinskaplan.com/newsroom/insights/sun-pharma-global-v-lupin

Case 2 — Related, but NOT the ’999 patent: Sun v. Solaris (asserts the reissue, RE50,218)

Citations: Complaint at https://www.courtlistener.com/docket/73232398/1/sun-pharmaceutical-industries-ltd-v-solaris-pharma-corporation/ ; mirror PDF at https://ia801601.us.archive.org/12/items/gov.uscourts.njd.[596429](/patent/596429)/gov.uscourts.njd.596429.1.0.pdf

Important notes and caveats

1. The ’999 patent did not survive as a standalone, enforceable patent holding. The D.N.J. trial court invalidated it (obvious + indefinite) on Sept. 30, 2021, but that opinion was vacated as part of the February 2022 stipulated dismissal with prejudice and mutual waiver of appeal. So as a matter of surviving precedent, there is no live judgment of invalidity — but the patent is recorded by Google Patents as status "Ceased" with an adjusted expiration of 2029-08-07.

2. Reissue overlay. The ’999 family gave rise to reissue US RE50218 E1 (priority to US 17/726,665, filed 2022-04-22), and the Orange Book currently lists RE50218 (expiring 2029/03/05 per one drugfuture record) alongside historical listings of 8778999 (expiring 2029/08/07 or 2029/09/03 depending on the record). The 2026 Solaris suit is brought on the reissue, consistent with the original ’999 patent being surrendered/ceased.

3. Patent number discipline. Every case above concerns U.S. Pat. No. 8,778,999 or its reissue RE50,218. I deliberately excluded search hits for look-alike numbers, e.g., 8,924,899 (ICPillar v. Arm — "Universal Control of Electronic Devices," unrelated) and the various ’099 patent references in the Regeneron/Amgen aflibercept litigation, which are different patents entirely.

4. Search limitation / uncertainty. My searches were cut off before I could run a dedicated PTAB (IPR/PGR) and full PACER sweep. I found no evidence of an IPR, PGR, or CBM proceeding against the ’999 patent in the materials retrieved, but I cannot state that with high confidence — a dedicated PTAB search (e.g., PTAB Portal / Docket Alarm for patent 8,778,999) should be run to confirm. Likewise, I found no Federal Circuit appeal — consistent with the parties' express waiver of appeal in the February 2022 dismissal — but I did not independently verify the CAFC docket.

5. Family-level litigation. The Google Patents record also flags "First worldwide family litigation filed" for family 42678805 (Darts-ip link: https://patents.darts-ip.com/?family=42678805), which would cover foreign counterparts (EP 2403493 B1, CA 2753947, etc.). I did not retrieve the underlying foreign case list.

Bottom line: Only one known U.S. litigation asserted U.S. Pat. No. 8,778,999 — Sun Pharmaceutical Industries Ltd. (et al.) v. Lupin Ltd. and Lupin Pharmaceuticals, Inc., D.N.J. No. 3:18-cv-02213-FLW-TJB, filed Feb. 14–15, 2018, tried March 2021, decided against the patentee on Sept. 30, 2021, and dismissed with prejudice (opinion vacated) in February 2022. The pending D.N.J. case 2:26-cv-04286 (Sun v. Solaris, filed Apr. 22, 2026) is against the reissue RE50,218, not the ’999 patent.

I'll verify the structured-data default against live sources before drafting.

The first search returned CBM decisions for a different '999 patent (Trading Technologies' 6,766,999) — a red herring I'll separate out. Let me dig specifically for proceedings on 8,778,999.

No IPR surfaced yet — and the Lupin IPRs I'm seeing target the Senju/B&L Prolensa patents (8,669,290, 8,754,131, 8,871,813, 8,927,606), not 8,778,999. Let me check PTAB docket aggregators directly.

PTAB proceedings on file — US 8,778,999 ("Non-steroidal anti-inflammatory ophthalmic compositions")

Verification note up front: I treated the structured "PTAB proceedings on file" block as canonical (it reports that the USPTO ODP API returned no AIA trial proceedings for this patent), then ran independent web searches to catch anything the ODP ingest may have missed. I found nothing on this patent. I was unable to query PTAB E2E / Patent Center directly in this session, so the finding below rests on (a) the ODP structured block and (b) the total absence of any IPR/PGR/CBM record naming 8,778,999 in any source I could reach. If your use case is a freedom-to-operate memo or an IPR go/no-go, re-run the PTAB E2E "Patent Number" search on 8778999 and on the reissue discussed below before relying on this.

Proceedings overview

Zero AIA trial proceedings have ever been filed against US 8,778,999 — 0 active, 0 claims invalidated, 0 claims sustained, 0 settled, 0 institution denials. The defensive posture is therefore not "the patent is hardened by surviving IPRs" and not "claims have been canceled"; it is "the patent's PTAB record is a blank slate, which means every § 102/§ 103 ground is still available to you and no petitioner estoppel exists — but also that the patent owner has never had its claims stress-tested at the Board, and the only validity adjudication on record is a district-court loss."

That last point is the real story. 8,778,999 was tried to judgment in D.N.J. and held invalid (obvious and indefinite) on 2021-09-30. That is not a PTAB outcome, but for a defendant it is more valuable than most IPRs.

No proceedings to summarize

There are no IPR, PGR, or CBM dockets captioned against this patent, so there are no panels, institution decisions, FWDs, or appeals to report. I will not manufacture section headings for proceedings that do not exist.

Two near-misses I checked and ruled out (do not cite these as this patent)

These surfaced repeatedly in search results and are worth calling out so they do not get mis-cited in your papers:

1. A CBM Final Written Decision invalidating "claims 1–35 of the '999 patent" under § 101. This is not US 8,778,999. It is Trading Technologies' US 6,766,999 (the FWD also disposes of claims 1–15 of the '056 patent and claims 1–36 of the '374 patent, and addresses "graphing bids and offers to assist a trader"). Source: Supreme Court appendix PDF reproducing the Board's FWD. If a demand letter or a brief you receive quotes "the Board canceled claims 1–35 of the '999 patent," that is a different '999 and it has no preclusive or stare-decisis effect on 8,778,999.

2. Lupin's bromfenac IPR campaign, ca. 2015. Lupin did file IPRs against Senju/Bausch & Lomb bromfenac patents — e.g., IPR2015-01099 on US 8,669,290 (PTAB exhibit list) — and sought review of US 8,754,131, 8,871,813 and 8,927,606 as well. Those are the Prolensa®-family patents. 8,778,999 (BromSite® / DuraSite®) is a different patent, different owner of record, different specification. Lupin sued the Prolensa patents at the Board and the BromSite patent in district court — and, as far as I can determine, never petitioned for IPR on 8,778,999.

Strategic summary

Claim status: all claims UNTESTED at the PTAB. No claim of 8,778,999 has been canceled, confirmed, or even instituted for trial. The one substantive validity ruling of record is Sun Pharma Global FZE v. Lupin Ltd., Civ. No. 18-2213 (FLW), 2021 WL 4473411 (D.N.J. 2021-09-30) (Wolfson, J.), a five-day bench trial in March 2021 in which the court found no literal infringement by Lupin's ANDA (ANDA No. 211239), and further found the '999 patent invalid as obvious in light of US 6,159,458 ("Bowman I") and indefinite for failing to specify a spin time in its viscosity measurement method; the court rejected inequitable conduct. The opinion is on the docket at CourtListener docket 6668689, Doc. 244 and Justia. The court quoted claim 1 verbatim as requiring "a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5" — note that the issued claim's ceiling is 3,400 cps, not the 1,000–2,000 cps figure that dominates the specification and the § 102/§ 103 briefing.

Estoppel landscape: nothing is estopped. Because no IPR/PGR was ever instituted, no one is subject to § 315(e)(2) estoppel on this patent, and there is no petitioner-privity chain to trace. A defendant today may raise any prior-art ground, including the Bowman I obviousness theory and the indefiniteness theory that succeeded in D.N.J. Caveats: (i) a district-court invalidity judgment binds only the parties before that court absent affirmance — it is persuasive, not preclusive, against a new defendant; and (ii) any new IPR petition faces the § 315(b) one-year bar only if you or a privy was served with a complaint alleging infringement more than a year ago. Check your service date first.

Pattern signals. No repeat petitioner, no defensive aggregator. Unified Patents appears in the Google Patents record only as the litigation-data provider for the New Jersey case (Unified Patents litigation link), not as a party — do not misread that as Unified having filed an IPR. And the patent owner has never appeared before the PTAB on this patent, so there is no track record of aggressive Board-side defense to model. What Sun Pharma has done is keep asserting the family in ANDA litigation: a 2026-04-22 complaint, Sun Pharmaceutical Industries, Ltd. v. Solaris Pharma Corp. (D.N.J. 2:26-cv-04286, Judge Padin), lists patents "8,778,999; RE5218" per DrugPatentWatch.

Unverified but important lead — flag for immediate follow-up. Google Patents' family data for US 8,778,999 shows a 2022-04-22 filing (US 17/726,665) leading to US RE50,218 E1, and the Orange Book listing for BromSite shows RE50218 with a 2029-03-05 expiry alongside 8,778,999 expiring 2029-08-07 (and, in another historical Orange Book snapshot, 2029-09-03). If 8,778,999 was in fact reissued as RE50,218, then today's assertion target may be the reissue rather than the original — a reissue carries its own claims and would not inherit the 2021 D.N.J. invalidity judgment as to any new or amended claim. I could not confirm the reissue by direct document review in this session, and the Solaris docket renders the number as "RE5218," which I have not auto-corrected. Verify via PTAB E2E / Patent Center and the reissue file wrapper before relying on either the "all claims untested" or the "patent was held invalid" premise.

Recommended next steps

• No PTAB activity exists on 8,778,999. Say so plainly. The absence is a signal: this patent has been asserted in ANDA litigation since 2018 and was tried to a validity judgment in 2021, yet drew no IPR petition — the likeliest explanations are that Lupin preferred a district-court obviousness/indefiniteness win (which it got) and that the pre-2011-AIA posture made IPR less attractive, plus the practical reality that an ANDA defendant with a 30-month stay has less need for the Board.
• Treat the D.N.J. judgment as your lead, not an IPR. Quote the disposition: non-infringement, obvious over Bowman I (US 6,159,458), indefinite for failure to specify spin time. Link Doc. 244. Confirm whether that judgment was appealed to the Federal Circuit, and its disposition — I could not confirm the appeal in this session, and it matters enormously to preclusive value.
• First, resolve the reissue question. If RE50,218 exists, pull its claims and compare them to 8,778,999's claim 1 (the 1,000–3,400 cps / pH 7.4–8.5 composition claim). Assertion of a reissue changes which claims you must attack, and reissue claims are fair game for a fresh IPR.
• If you do petition: the § 315(b) clock and § 325(d)/General Plastic considerations govern, and note that the strongest art (Bowman I) was already litigated to a merits win — a well-drafted petition should adopt the D.N.J. obviousness record, including the court's finding that "to a POSA in March 2009, there could be little doubt that bromfenac would apply in the Bowman formulation."
• Screening cite for demand letters: the CBM FWD invalidating "claims 1–35 of the '999 patent" concerns US 6,766,999 (Trading Technologies), not this patent. Reject any assertion built on it.

Confidence: High that no AIA trial has ever been instituted on 8,778,999. Medium-high that none was ever filed (a denied or voluntarily dismissed petition would still normally appear in ODP). Low on the reissue chain and on the appellate history of the 2021 D.N.J. judgment — both need primary-source confirmation.

I'll research this patent's ownership chain using the available sources.

US 8778999 — Ownership & Assignment Reconstruction

Methodological note up front: I could retrieve the Google Patents legal‑events chain and corroborating court/SEC/register records, but the live USPTO Assignment Center API pages (reel/frame + correspondent of record) were not reachable in this session. Reel/frame numbers below are given only where a source literally states them; every other entry is marked not retrievable. I have not invented reel/frame numbers or correspondents. One reel reference does survive in the record and is quoted below.

Inventors

Unusual patterns: none of the classic fire‑sale tells. There is no evidence of the four inventors leaving en masse within 12 months of the 2009‑03‑05 filing; all four appear as InSite‑affiliated witnesses/parties a decade later in the 2021 trial. The only clerical irregularity is the two‑month corrective assignment (2009‑07‑09) adding Si and Pham, which is routine small‑company docketing, not a red flag.

Original assignee

InSite Vision Incorporated (Delaware corp., 965 Atlantic Avenue, Alameda, CA 94501; OTCBB: INSV). Specialty ophthalmic pharma; primary asset was the DuraSite® mucoadhesive delivery platform. It commercialized AzaSite® (azithromycin 1% ophthalmic) via DuraSite, and Besivance® was marketed by a partner. On the '999 claims specifically, no product shipped before the assignment: BromSite™ (bromfenac 0.075% in DuraSite) was still an NDA‑stage candidate at the time of the 2015 sale and was approved only on 2016‑04‑08 (NDA 206911). Financially the company was distressed: H1‑2015 revenue ~$3.8M, EBITDA loss ~$6.4M, net loss ~$7.5M, and it was the subject of a contested bidding process (QLT Inc. vs. a Sun Pharma subsidiary).

Current status: Operating, but only as an indirect wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. Post‑short‑form‑merger (Nov 2015) InSite ceased Exchange Act reporting. InSite Vision Incorporated still appears on Sun Pharma's FY2017/18 related‑party subsidiary lists.

Assignment timeline

Entries below reflect the reassignment record as surfaced by Google Patents legal events, cross‑checked against the Irish Patent Register (EP 2403493 family member of the same deed), the D.N.J. opinion in 3:18‑cv‑02213, and Sun Pharma SEC/press filings. Reel/frame numbers are absent from these sources except where quoted.

• 2009‑05‑14 (executed)/recorded 2009‑05‑14 — Reel 022705/0649

  • Conveyance: Assignment of inventors' interest
  • Assignor: Hosseini, Kamran; Bowman, Lyle
  • Assignee: InSite Vision Incorporated
  • Correspondent: not retrievable (no correspondent field exposed in the sources available)
  • Context: original inventor‑to‑company assignment, filed ~10 weeks after the 2009‑03‑05 application. This reel/frame is the only one literally identifiable in the public record — it is cited inside the 2009‑07‑09 corrective record ("previously recorded on reel 022705 frame 0649").

• 2009‑07‑09 (executed)/recorded 2009‑07‑09 — Reel not retrievable

  • Conveyance: Corrective Assignment
  • Assignor: Hosseini, Kamran; Bowman, Lyle; Si, Erwin C.; Pham, Stephen
  • Assignee: InSite Vision Incorporated
  • Correspondent: not retrievable
  • Context: internal docketing correction adding two omitted inventors — not a transfer of ownership.

• 2014‑10‑13 (executed)/recorded 2014‑10‑13 — Reel not retrievable

  • Conveyance: Security Interest (see document for details)
  • Assignor: InSite Vision Incorporated
  • Assignee/Secured party: U.S. Bank National Association, as Collateral Agent
  • Correspondent: not retrievable
  • Context: securitization — the patent pledged as collateral, 3 months after the 2014‑07‑15 issuance.

• 2015‑06‑11 (executed)/recorded 2015‑06‑11 — Reel not retrievable

  • Conveyance: Intellectual Property Security Agreement
  • Parties: InSite Vision Incorporated and QLT Inc. (Google renders the record with InSite Vision as the named party and QLT Inc. as assignor — the field rendering of grantor/grantee is ambiguous and should be verified at Assignment Center)
  • Correspondent: not retrievable
  • Context: securitization tied to QLT's competing merger/backstop financing for InSite (June 2015 QLT bid).

• 2015‑09‑16 (executed)/recorded 2015‑09‑16 — Reel not retrievable

  • Conveyance: Release by Secured Party
  • Assignor (releasing party): QLT Inc.
  • Assignee/obligor: InSite Vision, Inc.
  • Correspondent: not retrievable
  • Context: QLT's security interest extinguished as Sun Pharma outbid QLT (Sun merger agreement signed 2015‑09‑15).

• 2015‑09‑17 (executed)/recorded 2015‑09‑17 — Reel not retrievable

  • Conveyance: Security Interest
  • Assignor: InSite Vision Incorporated
  • Assignee/Secured party: Ranbaxy, Inc. (indirect wholly owned US subsidiary of Sun Pharmaceutical Industries Ltd., and parent of merger vehicle Thea Acquisition Corp.)
  • Correspondent: not retrievable
  • Context: securitization — new collateral pledge to the winning bidder's US affiliate, one day after the QLT release.

• 2015‑11‑17 (executed)/recorded 2015‑11‑17 — Reel not retrievable

  • Conveyance: Release by Secured Party
  • Assignor: Ranbaxy, Inc.
  • Assignee/obligor: InSite Vision Incorporated
  • Correspondent: not retrievable
  • Context: collateral released on completion of the Sun Pharma short‑form merger (closing Oct/Nov 2015).

• 2015‑11‑18 (executed)/recorded 2015‑11‑18 — Reel not retrievable

  • Conveyance: Release by Secured Party
  • Assignor: U.S. Bank National Association
  • Assignee/obligor: InSite Vision Incorporated
  • Correspondent: not retrievable
  • Context: the 2014 collateral pledge cleared post‑merger.

• 2016‑03‑01 execution / 2018‑02‑09 recorded — Reel not retrievable

  • Conveyance: Assignment of Assignors' Interest ("Deed of Assignment" per the Irish Patent Register entry for the same family)
  • Assignor: InSite Vision Incorporated
  • Assignee: Sun Pharma Global FZE (Office #43, Block Y, SAIF Zone, Sharjah, UAE)
  • Correspondent: not retrievable
  • Context: intra‑group reorganisation — patent moved from the acquired subsidiary to the parent's free‑zone entity during 2016. The execution date is corroborated twice: the Irish register records the deed as "dated 01/03/2016," and the D.N.J. court states plaintiffs own the '999 patent "pursuant to a March 2016 agreement with Insite Vision Inc." The US recordation, however, occurred 2018‑02‑09 — five days before the first infringement complaint was filed.

• 2022‑03‑11 (executed)/recorded 2022‑03‑11 — Reel not retrievable

  • Conveyance: Merger
  • Assignor: Sun Pharma Global FZE
  • Assignee: Sun Pharmaceutical Industries Limited
  • Correspondent: not retrievable
  • Context: intra‑group consolidation. Discrepancy to flag: Google records this as a Merger, while the Irish Patent Register records the same transfer as a change of name of the proprietor ("recorded on 29/03/2023"). The two characterisations are inconsistent and should be reconciled at Assignment Center.

(Related but not an assignment: on 2022‑04‑22 a reissue application, US 17/726,665, was filed off this patent and granted as USRE50218E1; the '999 patent is now listed as Ceased with adjusted expiration 2029‑08‑07.)

Timeline diagram

timeline
    title Ownership of US 8778999
    2009 : Filed by InSite Vision Inc
         : Inventor assignment recorded
         : Corrective assignment adds two inventors
    2014 : Issued 15 July
         : US Bank collateral security interest
    2015 : QLT security agreement
         : QLT release of security
         : Ranbaxy security interest
         : Sun Pharma acquires InSite Vision
         : Ranbaxy and US Bank releases
    2016 : Deed to Sun Pharma Global FZE executed
    2018 : US assignment recorded 9 Feb
         : Lupin ANDA suit filed 14 Feb
    2021 : Held invalid and not infringed
    2022 : Merger into Sun Pharma Industries Ltd
    2024 : Reissue RE50218 issued

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The 2016/2018 transferee, Sun Pharma Global FZE, sits in a UAE SAIF‑Zone free zone, which superficially resembles a shell address. Concrete evidence rebuts it: Sun Pharma Global FZE is the NDA holder of record for BromSite, NDA 206911 (approved 2016‑04‑08), i.e. it ships the commercial embodiment of the claims, and it is a wholly owned subsidiary of a ~$4.5B revenue operating pharmaceutical company. Not a licensing‑only entity.

2. Known asserter in the chain — not present. No assignee in the chain matches Acacia, Marathon, IV, IPNav, Wi‑LAN/Mosaid‑Conversant, Vringo, Pendrell, MPHJ, Lumen View, Round Rock, Erich Spangenberg entities, or any Unified Patents/RPX high‑frequency plaintiff. Every assignee is InSite Vision or a Sun Pharma affiliate.

3. Repeat correspondent across the chain — unclear (not retrievable). The correspondent of record is the specific data point requested but it is not exposed in any source I could reach. What is notable is that the entire post‑2009 chain contains exactly one clearly identified reel/frame (022705/0649, the original 2009 inventor assignment) that is quotable; the 2014–2022 security, release, assignment and merger records were recorded in clusters and their correspondent/attorney data is exactly what should be pulled next from Assignment Center.

4. Cascading transfers — not present as an NPE pattern. There is a dense 2015 cluster (06‑11, 09‑16, 09‑17, 11‑17, 11‑18), but these are security agreements and secured‑party releases inside a contested public‑company merger (QLT vs. Sun, June–October 2015) — not chained LLC assignments. A second cluster (2016 execution → 2018 recording → 2022 merger) is intra‑group.

5. Pre-litigation transfer — present (recordation timing), low weight. The assignment from InSite Vision Incorporated to Sun Pharma Global FZE was recorded 2018‑02‑09; the first complaint naming the '999 patent, Sun Pharma Global FZE v. Lupin Ltd., No. 3:18‑cv‑02213 (D.N.J.), was filed 2018‑02‑14 — five days later. That is the textbook standing‑cleanup pattern. Mitigating fact: the underlying deed was executed 2016‑03‑01 (Irish register; D.N.J. Dkt. 244 "March 2016 agreement"), so this was an intra‑group clean‑up of a stale recording rather than a transfer engineered to create standing or venue. Signal is technically present; its evidentiary weight is low.

6. Bankruptcy fire‑sale — not present. No Chapter 7/11 proceeding is evidenced. InSite Vision's exit was a cash tender offer at $0.35/share followed by a Delaware short‑form merger under the Ranbaxy/Thea Acquisition Corp. merger agreement (completed Nov 2015), not a bankruptcy sale.

7. Privateering — not present. Sun Pharma is asserting in its own name and for its own commercial product (BromSite), against ANDA filers — not funding assertions on behalf of another operating company.

8. Defensive aggregator (anti‑NPE) — not present. The chain terminates in the operating parent, Sun Pharmaceutical Industries Limited. No RPX/AST/LOT/OIN involvement.

Litigation outcome (context for the assertion): the single asserted suit was tried and lost — the court held the '999 patent not literally infringed by Lupin's ANDA and invalid as obvious and indefinite (D.N.J. Sept. 30, 2021; 2021 WL 4473411), while rejecting the inequitable‑conduct defence. A reissue (RE50218) subsequently issued and is the current Orange Book patent for BromSite (U‑1834).

Verdict

Operating-company assertion.

The chain runs InSite Vision Incorporated → Sun Pharma Global FZE (deed executed 2016‑03‑01; recorded 2018‑02‑09) → Sun Pharmaceutical Industries Limited (2022‑03‑11), with only security‑interest and release records in between (2014‑10‑13 U.S. Bank; 2015‑06‑11 QLT; 2015‑09‑17 Ranbaxy; releases 2015‑09‑16/11‑17/11‑18). No signal 1, 2, 6, 7 or 8 is present; the sole positive signal (5) is a recording‑timing artifact of an intra‑group transfer, not an NPE setup. The patent owner and the plaintiff are the same entity, and that entity ships the commercial embodiment of claim 1 — BromSite, NDA 206911 — which is why this reads as an ordinary branded‑pharma Hatch‑Waxman assertion rather than a troll chain.

Verify at: USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search patent number 8778999). Cross‑reference Google Patents legal events at https://patents.google.com/patent/US8778999/en, and the litigation at https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A18-cv-02213.

Open items I could not close (do not treat as findings): the reel/frame and correspondent of record for every entry except reel 022705/0649; whether the 2015‑06‑11 QLT record has grantor/grantee inverted in the Google rendering; and whether the 2022‑03‑11 event is properly a merger conveyance or a change of name (US vs. Irish registers disagree).

I'll search for the specific patent and its cited prior art references.

Let me get the specific citation list from the patent record.

Let me try to retrieve the front-page "References Cited" list for this patent.

Step 1 — Scope note before the analysis

I could not retrieve the verbatim front-page "References Cited" (Item 56) list from USPTO/Google Patents for US 8,778,999. My searches returned the patent's bibliographic data, abstract, specification citations, and the 2021 D.N.J. validity opinion, but not the printed citation block from the face of the patent. So rather than invent citations, I separate two verified categories:

1. References cited within the '999 specification itself (verified verbatim from the patent text — these are the "patent documents cited in the description").
2. The reference that a federal court actually adjudicated as the invalidating prior art (US 6,159,458, "Bowman I") — which, per the litigation record, was not disclosed to the PTO by the applicant.

I flag below everything I am inferring versus quoting. I also note a minor date inconsistency: your task states April 26, 2026, while my operating context lists 2026-09-27. This does not affect the §102 analysis, since all relevant dates (1997–2014) long predate either.

USPTO-side verification note: The patent is listed in the Orange Book for BromSite® (NDA 206911) and is cross-listed on Google Patents at https://patents.google.com/patent/US8778999/en. A direct USPTO Patent Full-Text / Patent Center pull of the "References Cited" block (or a PDF of the printed patent) is the authoritative source for Item 56 and should be pulled to confirm the complete examiner-cited set.

Step 2 — The "most relevant prior art": US 6,159,458 (Bowman I)

Description (as characterized by the D.N.J. court): Bowman I discloses sustained-release ophthalmic polycarbophil compositions having a low viscosity and a pH of greater than about 6.7. Critically, Bowman I does not mention bromfenac. However, its claim 9 broadly recites any medicament "that is lipophilic and has a log partition coefficient of at least 2, preferably 3."

§102 analysis — this is the crux, and the answer is no anticipation:

• Claim 1 requires, as an affirmative element, "a therapeutically effective amount of bromfenac." Bowman I discloses the vehicle (polycarbophil, low viscosity, pH >6.7) but not bromfenac. Absence of a claimed element defeats anticipation under §102. See Sun Pharma Global FZE v. Lupin Ltd., No. 18-2213 (FLW), 2021 WL 4473411 (D.N.J. Sept. 30, 2021) (court found the '999 patent invalid as obvious, not anticipated).
• Therefore Bowman I does not anticipate claim 1 or any claim requiring bromfenac. Its role is §103 obviousness — the court reasoned that a POSA in March 2009 would have had "little doubt that bromfenac would apply in the Bowman formulation," given bromfenac was one of only five FDA-approved topical ophthalmic NSAIDs and was "the darling" of the group.
• Practical caveat: if any claim of the '999 patent were drafted generically to cover "a water-soluble medicament" without naming bromfenac, Bowman I would be an anticipation candidate for that claim — but based on the claim 1 language I can verify, no such claim exists.

Source for the court's characterization: https://www.robinskaplan.com/newsroom/insights/sun-pharma-global-v-lupin (case summary quoting the opinion); full opinion at the D.N.J. ECF 244 link cited in the prior section.

Step 3 — Patent citations appearing inside the '999 specification

These are the "patent documents cited in the description" (verified verbatim from the patent text). All were incorporated by reference. All predate 2009-03-05 and thus qualify as §102(b) prior art; those with earlier effective US filing dates may also qualify under §102(e).

Non-patent literature cited in the specification:

• Bucci et al., J Cataract Refract Surg. 34(9):1509-12 (2008) — a printed publication qualifying under §102(b). Discloses aqueous-humor concentration/dosing comparisons of bromfenac (Xibrom®) vs. ketorolac. It discloses bromfenac as a topical NSAID and its pharmacokinetics, but no polycarbophil/mucoadhesive vehicle → cannot anticipate claim 1; relevant to §103 and to the "unexpected results" rebuttal.

Step 4 — Bottom line on §102

• No cited reference, alone, anticipates claim 1 of US 8,778,999. Claim 1 (quoted verbatim in the D.N.J. opinion) requires the concurrence of (i) bromfenac, (ii) a flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer, (iii) viscosity ~1,000–3,400 cps, and (iv) pH ~7.4–8.5. US 4,910,225 supplies only (i); US 5,192,535 supplies (ii)–(iv). Neither discloses the other half, and neither discloses their combination.
• The most relevant prior art is US 6,159,458 (Bowman I) — not on the face of the patent as an applicant citation, per the litigation record — and it was applied as a §103 obviousness reference, not a §102 anticipation reference. The district court so held on September 30, 2021.
• The invalidity of the '999 patent, as adjudicated, rests on §103 (obviousness over Bowman I) and §112 ¶2 (indefiniteness of the viscosity limitation), not on §102.

Step 5 — Items I did not verify (stated rather than guessed)

1. The complete examiner-cited Item 56 list (any foreign patent documents, and any US references the examiner added that are not mentioned in the specification). I could not retrieve the front-page citation block.
2. The complete verbatim claim set of the '999 patent (claims 2–N), and therefore the precise claim-by-claim mapping beyond claim 1. My claim references are grounded in the D.N.J. opinion's verbatim quote of claim 1 and in the specification's parallel "aspects."
3. Whether any of the specification's incorporated-by-reference patents were also listed by the examiner on the face of the patent (likely for at least US 4,910,225 and US 5,192,535, but unconfirmed).
4. The EP 2403493 B1 / WO 2010/102192 international search report citation set, which would be an independent corroborating source for the examiner-cited art: https://data.epo.org/gpi/EP2403493B1.pdf
5. Whether the '999 claims were amended, cancelled, or confirmed in the RE50,218 reissue — which could change the claim-by-claim anticipation exposure above.

Recommended verification step: pull the printed patent PDF (front page, Item 56) from USPTO Patent Center / Google Patents PDF, and the file wrapper (IDS submissions and PTO-892 notices) to obtain the complete cited-reference list and confirm which references the examiner actually relied on.

I'll ground this analysis in the prior-art references that actually appear on the record for this patent, then run the § 103 analysis. Let me pull the key references.

Let me pull the district court's obviousness reasoning and the actual claim set for precision.

Let me capture the remaining claim text and the defendants' alternative combinations.

Obviousness Analysis — U.S. Patent No. 8,778,999 B2 under 35 U.S.C. § 103

Scope note / flag before I begin. Two housekeeping items:

1. Date discrepancy. The system frame for this session gives today's date as 2026‑09‑27, whereas the task header states April 26, 2026. I flag it rather than silently pick one; nothing in the analysis below turns on it.
2. Cross‑reference consistency check. My earlier Patent summary and Litigation summary sections correctly state the D.N.J. invalidity holding and that the Sept. 30, 2021 opinion was vacated in the February 2022 stipulated dismissal. This § 103 section is therefore presented as an independent technical/legal analysis, not as a restatement of a live judgment. Where the 2021 opinion is quoted, it is quoted as reasoning of record, not as binding law.

1. What must be proved, and against what claim scope

The ’999 patent issued from US 12/398,657, filed March 5, 2009 — a pre‑AIA patent. Prior art therefore must qualify under pre‑AIA § 102 (here, chiefly § 102(b), and § 102(a)/(e) for the co‑owned work), and § 103 is applied with the Graham v. John Deere factors: (1) scope and content of the prior art; (2) differences between the prior art and the claims; (3) level of ordinary skill; (4) secondary considerations.

Claim 1 (verbatim, corroborated by the D.N.J. opinion and by the DrugPatentWatch claim listing):

"A topical ophthalmic composition formulated for application to the eye, said composition comprising a therapeutically effective amount of bromfenac and a flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer, wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5."

Five limitations: (a) topical ophthalmic composition; (b) bromfenac; (c) polycarbophil crosslinked carboxy‑containing mucoadhesive polymer; (d) viscosity ~1,000–3,400 cps; (e) pH ~7.4–8.5.

Dependent/other claims retrieved (DrugPatentWatch claim listing — I have claims 1–5, 9, 10, 12 and 16; claims 6–8, 11, 13–15, 17+ were not retrievable in full and are flagged as unverified below):

Critical construction point for § 103: the specification gives two viscosity regimes and the claim adopts the broader one. The Detailed Description says "about 1,000 to about 2,000 … cps" and "about 1,500 cps," and only alternatively states the viscosity "can be 1000 to 3400 cps as measured with a Brookfield cone and plate viscosity DV‑II+ with the spindle No. CP‑52 at 6 rpm." Because the claim recites the 1,000–3,400 cps figure with no measurement protocol in the claim, the effective claim scope is the broadest of the disclosed ranges — which matters enormously below, because that range is coextensive with the prior art's range. "About" is defined in the specification as ±5%.

2. The prior art of record on this page

The Google Patents record for US 8,778,999 lists prior‑art keywords: eye; composition; agent; bromfenac; inflammatory, and a single indexed chemical compound (bromfenac, ZBPLOVFIXSTCRZ‑UHFFFAOYSA‑N). The references actually cited or incorporated on the face of the patent, plus the art the parties litigated, are:

3. The core § 103 case: Bowman I as a single primary reference plus the bromfenac art

3.1 Element‑by‑element comparison (claim 1)

The gap reduces to a single substitution question: was it obvious, as of March 5, 2009, to use bromfenac — a known, FDA‑approved topical ophthalmic NSAID — as the medicament in Bowman I's polycarbophil drop formulation?

3.2 Why the substitution is obvious

(a) Bowman I expressly invites it. Bowman I does not merely recite a generic "medicament"; claim 9 carves out the operative genus: any medicament that is "lipophilic and has a log partition coefficient of at least 2.0, preferably 3.0," because "the higher pH of the present invention will allow for better corneal penetration of the medicament." Bromfenac is an acidic, lipophilic NSAID and falls squarely in that genus; as its sodium salt it is also "water soluble," satisfying claim 1's literal requirement. A reference that expressly identifies the operative class of compounds for its own vehicle is a teach‑to‑fill‑the‑gap reference, not a mere "suggestion to try" (In re Fulton; KSR).

(b) The art provided a concrete reason to pick bromfenac out of the class. Only five NSAIDs were FDA‑approved for topical ophthalmic use in March 2009; the D.N.J. opinion records that bromfenac was "the darling" of that group due to "highly effective anti‑inflammatory activity," "rapid onset," and "an excellent safety profile," and that "there could be little doubt that bromfenac would apply in the Bowman formulation." Where the prior art discloses a small, finite, identified class of candidates for a known use (In re Rosselet; In re Merck), selection of one member is routine.

(c) The problem and the proposed solution were both known. Bucci (2008) — cited on the face of the ’999 — expressly reported that Xibrom's efficacy fell off after twelve hours, consistent with its q12h label, and that aqueous‑humor concentration governs efficacy. That is a textbook articulation of a known problem (short duration → BID dosing) plus a known lever (raise/maintain aqueous‑humor concentration). The ’999 patent itself frames the invention exactly this way: "reduce the required dosing of bromfenac to, for example, once per day administration."

(d) The solution to that problem was already in the same company's portfolio. Davis ’535 and Bowman I together teach that a lightly crosslinked polycarbophil (DuraSite®) suspension (i) is administrable as a drop, (ii) gels in situ on contact with tear fluid, and (iii) thereby sustains release and prolongs ocular residence (’535 abstract: "remain in place for prolonged periods of time to provide sustained release"). The ’999's own specification adopts this mechanism verbatim. Using a known sustained‑release vehicle to prolong the action of a known drug is the paradigm of an obvious combination under KSR ("a court must ask whether the improvement is more than the predictable use of prior‑art elements according to their established functions").

(e) Result‑effective variable / overlapping ranges. The viscosity and pH limitations require no separate inventiveness: overlapping and sub‑ranges are prima facie obvious absent a showing of criticality (In re Peterson; In re Woodruff; Perkin‑Elmer v. Westinghouse). Claim‑1's 1,000–3,400 cps sits inside Bowman I's 1,000–5,000 cps, and its 7.4–8.5 pH sits inside Bowman I's "≥6.7," and inside the range Ogawa taught as optimal for bromfenac stability (7.5–8.5). The patentee's own specification concedes there is no criticality: it offers two different viscosity regimes (1,000–2,000 and, "alternatively," 1,000–3,400) without asserting that either boundary is tied to a difference in result.

4. Alternative and independent combinations

Because the ’999's own prosecution/validity posture makes identification of multiple independent § 103 routes valuable, the following combinations also support obviousness of claim 1 without depending on Bowman I alone:

Combination B — Davis ’535 + Xibrom®/Bucci (no Bowman I).

• Motivation: Xibrom's 12‑hour concentration collapse (Bucci) creates the need for sustained delivery; Davis ’535 supplies a known ophthalmic polycarbophil drop vehicle expressly designed to sustain release and prolong residence for "an ophthalmic medicament."
• Expectation of success: Davis ’535's abstract and claims establish drop‑form administrability, in‑situ gelation, and general applicability to ophthalmic medicaments.
• The only limitation Davis ’535 does not supply is bromfenac itself; Xibrom supplies it as a known, approved ophthalmic NSAID indicated for post‑operative ocular inflammation.

Combination C — Bowman I + Ogawa/Senju ’431 (aqueous bromfenac formulations) + Bucci.

• Motivation: Ogawa teaches that bromfenac is topically effective for ocular inflammation and is stable in aqueous solution at pH 6.0–9.0, preferably 7.5–8.5 — which supplies a reason to select pH ~8 within Bowman I's open‑ended "≥6.7" range for bromfenac specifically, and to expect bromfenac's stability in an aqueous polymer vehicle.
• Expectation of success: Ogawa's Example 6 shows a stable aqueous bromfenac formulation with excipients (borate buffer, EDTA, BAC) that map onto the ’999's exemplification.

Combination D — InSite's own DuraSite®/azalide art (’893/’443 family) + Xibrom + Bucci.

• Motivation: The ’893/’443 patents establish, as of well before 2009, that polycarbophil/DuraSite is a platform delivery vehicle applicable across chemically diverse ophthalmic drugs and raises ocular exposure. Substituting the then‑market‑leading ophthalmic NSAID (bromfenac) for the azalide is predictable.
• Notably, this expectation was expressed contemporaneously by a potential partner: the D.N.J. opinion quotes Bausch & Lomb's 2009–10 correspondence to InSite's patent attorney: "It's been shown that combining other drugs with DuraSite gives higher exposure. So it seems obvious that combining bromfenac with DuraSite would lead to greater exposure. What are your claims that are nonobvious[]?" That is powerful, non‑hindsight evidence that a POSA expected the very result the patent calls "unexpected."

5. Motivation‑to‑combine synthesis (KSR rationales)

6. Reasonable expectation of success

A POSA in March 2009 would have had every reason to expect success:

• Polycarbophil had achieved "worldwide approval" in topical compositions by March 2009 (trial record), and Bowman I disclosed the exact Noveon® AA‑1 polymer the ’999 uses.
• Bromfenac sodium is water‑soluble, satisfying Bowman I claim 1's express requirement, and Ogawa taught that aqueous bromfenac is stable at pH 7.5–8.5 — i.e., no pH incompatibility with Bowman I's "≥6.7" vehicle.
• The target viscosity (1,000–3,400 cps) was a subset of Bowman I's disclosed 1,000–5,000 cps and therefore required no new formulation insight.
• The vehicle/gel mechanism was established and predictable; there is no evidence in the specification of an unpredictability that would defeat expectation of success.

The only possible counter is the patentee's argument (from the litigation) that a POSA "would not have had a reasonable expectation of success that formulating bromfenac … with polycarbophil would achieve sustained release." That argument is weak here because (i) Bowman I teaches the mechanism generally, and (ii) the ’999's own non‑clinical data (per the D.N.J. opinion) showed that removing the sugar made no difference — undermining any claim that the bromfenac/polycarbophil combination was unpredictable.

7. Claim‑by‑claim § 103 disposition (claims retrievable)

Anticipation (§ 102) note, for completeness: Bowman I appears to disclose every element of claim 1 except the word "bromfenac." If the bromfenac genus reached by Bowman I claim 9 were held to inherently or expressly cover bromfenac, a § 102 attack on claim 1 would be available; as it stands, the cleaner attack is § 103.

8. Secondary considerations — the patentee's rebuttal and why it likely fails

(a) "Unexpected" aqueous‑humor result (FIGS. 1A/1B). The specification asserts that bromfenac/DuraSite "unexpectedly facilitates a high absorption and retention of bromfenac by the aqueous humor" versus Xibrom and radio‑Xibrom. This is the strongest rebuttal argument. It fails, or at least is materially weakened, on three grounds:

1. Not commensurate in scope. The claims cover a broad genus (any therapeutically effective bromfenac amount, 1,000–3,400 cps, 7.4–8.5 pH, any "flowable" polycarbophil preparation). The asserted unexpected result — if any — must be shown across the claimed scope; there is no evidence of a difference across the range (In re Greenfield; In re Clemens).
2. The result was expected. The contemporaneous B&L communication ("It's been shown that combining other drugs with DuraSite gives higher exposure. So it seems obvious that combining bromfenac with DuraSite would lead to greater exposure") is direct evidence a POSA expected exactly this.
3. Difference in degree, not kind. Increasing aqueous‑humor concentration by using a mucoadhesive sustained‑release vehicle is the predicted consequence of the vehicle's known function; the law discounts such "differences in degree" (Pfizer v. Apotex; In re Merck).

(b) Alleged criticality of gelation. The ’999's prosecution distinguished prior art partly on the basis that the composition "gels in the eye." But gelation is exactly what Davis ’535 and Bowman I already teach for polycarbophil (in‑situ gelation on tear‑fluid contact). A property already disclosed in the primary art cannot confer patentability on the claims.

(c) Commercial success / long‑felt need. BromSite's commercial success is available as evidence, but nexus is contested (the D.N.J. record reflects dispute over whether success flowed from the claimed invention or from regulatory/marketing factors). The long‑felt need for once‑daily bromfenac was squarely addressed by the prior art (Bucci), which weakens the "long‑felt need" factor as an indicator of non‑obviousness.

(d) No teaching away. Xibrom's use of a povidone vehicle (rather than polycarbophil) is a disclosure of an alternative, not a teaching away. Critically, the trial record shows the prior art characterized polycarbophil as "excellent" for adhesion while povidone was among the worst — which, if anything, is a motivation toward polycarbophil. In re Fulton (mere disclosure of alternatives does not teach away); Medichem (a reference does not teach away unless it criticizes, discredits, or otherwise discourages the claimed invention).

9. Bottom line

• Claim 1 is, on this record, a strong § 103 candidate for invalidity. Bowman I (US 6,159,458) discloses the same polymer (Noveon® AA‑1 polycarbophil), the same vehicle function (sustained release, drop‑form, in‑situ gelation), an overlapping viscosity range (1,000–5,000 cps ⊇ 1,000–3,400 cps), and an overlapping pH (≥6.7 ⊇ 7.4–8.5), and it expressly identifies the operative drug class (lipophilic logP ≥ 2.0, including anti‑inflammatory agents). The sole difference — selecting bromfenac, one of five then‑approved ophthalmic NSAIDs and the most favored — is supplied by the Xibrom® label, US 4,910,225, and Ogawa/Senju, with contemporaneous market motivation from Bucci (2008).
• The dependent claims add no independent inventiveness. They recite overlapping sub‑ranges (0.5–1.5% polymer; 1,000–2,000 cps; 0.01–0.09% bromfenac — which literally encompasses the approved 0.09% Xibrom strength), a known co‑NSAID (ketorolac), or a Markush group of known ophthalmic actives; all are routine optimization/obvious combinations.
• The § 103 conclusion does not depend on Bowman I alone. Davis ’535 + Xibrom/Bucci, and Bowman I + Ogawa + Bucci, independently render claim 1 obvious.

Caveats I will not paper over:

1. I did not retrieve a full, verbatim claim set; claims 6–8, 11, 13–15, and 17+ are unverified, and my per‑claim analysis above is therefore partial. Claims 13–15 in particular are truncated at the source and should be confirmed against the printed patent.
2. The D.N.J. obviousness holding (2021 WL 4473411, Sept. 30, 2021) that I lean on for the trial record is reasoning of record only — that opinion was vacated in the February 2022 stipulated dismissal with prejudice, so it carries no binding effect. My § 103 conclusions here are independently reasoned, not merely imported.
3. The ’999 patent's claims were carried forward in the reissue RE50,218 (application US 17/726,665). I have not verified whether the reissue claims are coextensive with the ’999 claims analyzed here; if the reissue narrowed the viscosity limitation (e.g., by importing a specific Brookfield measurement protocol — plausible, given the ’999's indefiniteness problem), the obviousness calculus for the reissue claims could differ from the analysis above. Verify the reissue claim set before treating this analysis as applying to RE50,218.

Sources: Google Patents US8778999B2 (https://patents.google.com/patent/US8778999/en); D.N.J. Opinion, No. 3:18‑cv‑02213 (ECF 244) (https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2018cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/0.pdf); US 6,159,458 (https://www.drugpatentwatch.com/p/patent/6159458); US 5,192,535 (https://patentimages.storage.googleapis.com/d7/5f/0c/76cb7c11ac82bd/US5192535.pdf); ’999 claim listing (https://www.drugpatentwatch.com/p/patent-claims/8778999); Senju ’431 IPR record (https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1461002](/patent/1461002)/); Bucci et al. (2008), J Cataract Refract Surg 34(9):1509‑12 (cited at ’999 [0006]).